JOHN HUBBARD: Open Payments
NPI 1881640555 · TUSCALOOSA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,654 in 174 payments from 16 companies in 2025. Trend: 2023 $2,474 · 2024 $4,067 · 2025 $4,654
Food & beverage: $4,583Education: $71
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 29 | $721 |
| ABBVIE INC. | 20 | $638 |
| Vanda Pharmaceuticals Inc. | 21 | $627 |
| E.R. Squibb & Sons, L.L.C. | 15 | $588 |
| Otsuka America Pharmaceutical, Inc. | 13 | $412 |
| Neurocrine BioSciences, Inc. | 25 | $405 |
| Teva Pharmaceuticals USA, Inc. | 14 | $309 |
| Axsome Therapeutics, Inc. | 7 | $212 |
| Janssen Pharmaceuticals, Inc | 5 | $190 |
| Bausch Health US, LLC | 7 | $159 |
Products named: CAPLYTA, VRAYLAR, COBENFY, FANAPT, INGREZZA, ABILIFY MAINTENA, Auvelity, HETLIOZ.
Industry payments across AL — which companies pay providers there.
